BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24474639)

  • 1. Successful peripheral blood stem cell mobilization using pegfilgrastim in allogeneic stem cell transplantation.
    Chanswangphuwana C; Kupatawintu P; Panjai P; Tunsittipun P; Intragumtornchai T; Bunworasate U
    Int J Hematol; 2014 Mar; 99(3):318-22. PubMed ID: 24474639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem-cell mobilization of healthy sibling donors with pegfilgrastim-A prospective open-label phase II trial (EudraCT no: 2005-004971-39).
    Vucinic V; Jentzsch M; Leiblein S; Bach E; Remane Y; Schulze-Forster K; Cross M; Pönisch W; Schwind S; Franke GN; Platzbecker U; Niederwieser D
    Transfusion; 2022 Jan; 62(1):157-164. PubMed ID: 34893987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors.
    Kroschinsky F; Hölig K; Poppe-Thiede K; Zimmer K; Ordemann R; Blechschmidt M; Oelschlaegel U; Bornhauser M; Rall G; Rutt C; Ehninger G
    Haematologica; 2005 Dec; 90(12):1665-71. PubMed ID: 16330441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of single-dose 6 mg pegfilgrastim in mobilizing peripheral blood stem cells in allogeneic hematopoietic cell transplantation donors.
    Cao J; Li A; Pei R; Lu Y; Chen D; Du X; Liu X; Li S; Ye P
    Ann Hematol; 2023 Dec; 102(12):3567-3573. PubMed ID: 37773294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization.
    Kuan JW; Su AT; Wong SP; Sim XY; Toh SG; Ong TC; Rajasuriarr JS; Lim SH; Guan YK; Liew HK; Liew PK; Tan JT; Kori AN; Cheng YY; Tan SM; Chang KM
    Transfus Apher Sci; 2015 Oct; 53(2):196-204. PubMed ID: 25910537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
    Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
    Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
    Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
    Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy.
    Bassi S; Rabascio C; Nassi L; Steffanoni S; Babic A; Bertazzoni P; Gigli F; Antoniotti P; Orlando L; Sammassimo S; Quarna J; Negri M; Martinelli G
    Transfus Apher Sci; 2010 Dec; 43(3):321-326. PubMed ID: 21036667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
    Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
    Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
    J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis.
    Hsu JW; Wingard JR; Logan BR; Chitphakdithai P; Akpek G; Anderlini P; Artz AS; Bredeson C; Goldstein S; Hale G; Hematti P; Joshi S; Kamble RT; Lazarus HM; O'Donnell PV; Pulsipher MA; Savani BN; Schears RM; Shaw BE; Confer DL
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):165-71. PubMed ID: 25316111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and kinetics of CD34
    Takhar H; Mislang AR; Singhal N; Brown MP
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):79-86. PubMed ID: 27649817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.
    Hill GR; Morris ES; Fuery M; Hutchins C; Butler J; Grigg A; Roberts A; Bradstock K; Szer J; Kennedy G; Morton J; Durrant S
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):603-7. PubMed ID: 16737933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and efficacy of low-dose pegfilgrastim for CD34
    Goto H; Hidaka D; Yamamoto S; Hayasaka K; Michimata R; Kagawa I; Sunagoya K; Iijima H; Hayase E; Shiratori S; Okada K; Sugita J; Onozawa M; Hashimoto D; Kahata K; Fujimoto K; Endo T; Shimizu C; Teshima T;
    J Clin Apher; 2020 Sep; 35(5):413-419. PubMed ID: 33043486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors.
    Suzuya H; Watanabe T; Nakagawa R; Watanabe H; Okamoto Y; Onishi T; Abe T; Kawano Y; Kagami S; Takaue Y
    Vox Sang; 2005 Nov; 89(4):229-35. PubMed ID: 16262756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of single-dose G-CSF in mobilization and reconstruction of allogeneic peripheral blood stem cell transplantation].
    Tian H; Zhou SY
    Ai Zheng; 2003 Dec; 22(12):1325-9. PubMed ID: 14693061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
    Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
    Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.